This inventor holds 2 USPTO granted patents and 6 published patent applications and 1 EPO patent. Top assignees: Genentech, Inc., Shanghai Pangood Power Technology. Active years: 2020-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2026
Title: Innovations of Jinhua Chen in Drug Conjugates
Introduction
Jinhua Chen is a notable inventor based in Shanghai, China. He has made significant contributions to the field of drug conjugates, particularly through his innovative patent related to hindered disulfide drug conjugates. His work is essential in advancing targeted drug delivery systems.
Latest Patents
Jinhua Chen holds a patent for "Hindered disulfide drug conjugates." This invention relates to disulfide drug conjugates wherein a linker, comprising a sulfur-bearing carbon atom substituted with at least one hydrocarbyl or substituted hydrocarbyl, is conjugated by a disulfide bond to a cysteine sulfur atom of a targeting carrier. The linker is further conjugated to a drug moiety. Additionally, the invention includes activated linker-drug conjugates suitable for conjugation to a targeting carrier by a disulfide bond, along with methods for preparing these hindered disulfide drug conjugates. He has 1 patent to his name.
Career Highlights
Jinhua Chen is currently employed at Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. His work at Genentech has allowed him to focus on groundbreaking research in drug conjugates, contributing to advancements in therapeutic applications.
Collaborations
Jinhua Chen has collaborated with notable colleagues, including Peter Scott Dragovich and Zhonghua Pei. These collaborations have fostered a productive environment for innovation and research in the field of drug delivery systems.
Conclusion
Jinhua Chen's contributions to the field of drug conjugates exemplify the importance of innovation in medicine. His work continues to influence the development of targeted therapies, showcasing the potential of scientific advancements in improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
